Trilavir MINI is a fixed-dose combination antiretroviral medication formulated for the treatment of HIV-1 infection. It is designed as a lower-strength or pediatric-friendly version of Trilavir, making it suitable for children, adolescents, or adults requiring dose adjustment. It typically contains Lamivudine, Tenofovir Disoproxil Fumarate, and Efavirenz in reduced doses to ensure safety and efficacy.

Mechanism of Action

Trilavir MINI combines three classes of HIV-fighting agents that work synergistically to inhibit viral replication:

1. Tenofovir Disoproxil Fumarate (TDF) – a nucleotide reverse transcriptase inhibitor (NtRTI) that blocks the reverse transcriptase enzyme, preventing viral DNA formation.

2. Lamivudine (3TC) – a nucleoside reverse transcriptase inhibitor (NRTI) that incorporates into viral DNA, causing chain termination.

3. Efavirenz (EFV) – a non-nucleoside reverse transcriptase inhibitor (NNRTI) that binds directly to reverse transcriptase and inhibits its function.

   Uses

   • Management and treatment of HIV-1 infection.

   • Helps suppress viral replication and maintain low viral load.

   • Used as part of combination antiretroviral therapy (ART).

   • May be prescribed for adolescents or patients needing lower-dose therapy.

     Adverse Effects

     • Dizziness, headache, or tiredness

     • Nausea, vomiting, diarrhea

     • Insomnia or vivid dreams (due to Efavirenz)

     • Mild rash